Conference Scope:
Polymer Therapeutics are amongst the most successful first generation “Nanomedicines”. A growing number of products have been approved by Regulatory Authorities for routine clinical use and others are progressing through clinical trials as single agents or as components of combination therapy regimes.
Polymer Therapeutics include inherently biologically active polymeric drugs and polymeric sequestrants, polymer-protein and polymer-drug conjugates, block copolymer micelles, and the supramolecular assemblies that form multi-component polyplexes designed to promote cytosolic delivery of genes, siRNAs and proteins.
Ever more sophisticated synthetic chemistry is leading to complex three dimensional polymeric architectures, including dendrimers, dendronised polymers and self-assembling nano-sized particles. Many polymeric carriers and hybrid polymer-coated systems are being developed as imaging agents and theranostics.
As clinical applications broaden to include treatments for infectious and inflammatory diseases, tissue repair and regeneration, and diseases of the ageing population there has been growing interest in the use of biodegradable polymers that are more suited to use for chronic treatments.
Plenary Lectures:
- Virgil Percec (Univ. Pennsylvania) • Dendrimers, dendrimersomes and other complex architectures with potential for drug delivery
- Bernhards Ogutu (Kenya Medical Research Inst.) •The challenge of diseases of poverty in Africa
- Scott E. McNeil (Nanotech Characterization Lab, NCI) • Challenges for the translation of advanced nanomedicines into clinical development
- Michelle Bradbury (Memorial Sloan Kettering Cancer Center) • Development of Multimodal (including PET) Imaging platforms: Design, Evaluation and Translation from Lab to Clinic”
Please visit the conference website for additional information & registration:
